drugset / Trial / NCT00393835

A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

NCT00393835

Phase 3 Completed 99 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.

Timeline

Start
2006-11
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 2 g